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Summary for the MPKSN Report (For publication in the Annual MPKSN 
Report, please summarise the project objectives, significant results 
achieve, research approach and team structure) 
The objective of the project was to oonstrud plasmid(s) expressing specific genes of 
Mycobacterium tuberculosis (MTB): towards the development of potential DNA 
vaccine candidates against tuberculosis. Several T -cell epitopes from various 
specific genes of MTB were selected which include ESAT-6, MTP40, MPT64 and · 
38k0a. In order to construct the synthetic gene consists of those selected epitopes, 
the innovative PCR technology known as 'Assembly PCR' was employed. In this 
project, the synthetic gene (consist of multiple epitopes of M. tuberculosis) was 
successfully constructed and the gene is designated as vacll. The vacll was then 
cloned into plasmid DNA vector, pJW4303. The recombinant plasmid containing the 
vacll designated as pJWvacll was obtained. The DNA sequence of the cloned gene 
(vacll) or the insert was confinned by DNA sequencing method. So, in this project, 
we have constructed one DNA vaccine candidate for tuberculosis. Further studies 
that to be done to evaluate this vaccine candidate include immunogenecity and 
protection efficacy in animal model. 
In this projed, the immunogenicity of pJWvacll was studied in mice in order to 
detennine its ability to induce various immune responses. Mice were immunised with 
the pJWvacll and control plasmid (pJW blank vector). At the end of the immunisation 
protocol, the spleenic lymhocytes were prepared from the two groups of mice. 
Lymphocyte responses in vitro were determined by Flow Cytometric analyses, 
Lymphocyte Transformation Test and IFN gamma production {by ELISA) after 
culturing them with several peptides derived from the vacll construct. 
Results of Flow Cytometry which measure lymphocyte activation status did not 
show any signifteant different between the control and test group. But, results of 
LTT and IFN gamma production showed that some mice vaccinated with pJWvacll 
were positive when compared to the control group. These results indicated that the 
DNA vaccine candidate (pJWvacll) is immunogenic in mice ie. able to induce 
immune response. The ability of pJWvacll to induce IFN gamma production 
suggested that the DNA vaccine construct stimulated the Th1 type of immune 
response which is essential for immunity to TB. However, more studies need to be 
done to confirm these prilimanary findings. Such studies include protection or 
challenge studies in mice but this part of the study can be done here due to lack of 
facility required. 
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Objectives achievement 
• 
• Original project objectives (Please state the specific project objectives 
as described in Section II of the Application Form) 
-To clone genes/epitopes of M.tuberculosis into a plasmid (pCMV). 
- To prepare DNA constructs/recombinant protein for vaccination. 
- To study antibody and T -cell responses of the vaccinated animals. 
• Objectives Achieved (Please state the extent to which the project 
objectives were achieved) 
We have succesfully constructed a plasmid expressing multiple T -cell epitopes of 
M. tuberculosis as DNA vaccine candidate for tuberculosis. 
• Objectives not achieved (Please identify the objectives that were not achieved and 
give reasons) 
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Technology Transfer/commercialisation Approach (Please describe the ap,proach 
planned to transferlcommerciaHse the results of the project) 
This project has established recombinant DNA technology/approach especially 
assembly PCR technique for DNA vaccine development. This technology is not only 
usefull for TB but also for other diseases in future. This technology can be 
transferred to other research institutions/universities in this country. 
Benefits of the Project (Please identify the actual benefits arising from the project as 
defined in Section Ill of the Application Fonn. For examples of outputs, organisational 
outcomes and sectoraVnational impacts~ please refer to Section Ill of the GuideHnes for the 
AppHcation of R & D Funding under IRPA) 
• Outputs of the project and .potential beneficiaries (Please describe 
as specically as possible the outputs achieved and provide an assessment 
of their significance to users) · 
Laboratory set up/technology for DNA vaccines development can be a trainning 
center for other reseachers in this country. 
- The plasmid DNA construct (DNA vaccine candidate} obtained from this project 
has potential for further vaccine development as an alternative vaccine for the 
prevention and control of TB. 
• Organisational Outcomes (Please describe as specifically as possible 
the organisational benefits arising from the project and provide as 
assessment of their significance) 
estabfised training center for other reseachers/postgraduate students in this 
counby with regards to recombinant DNNPCR technology. 
• National Impacts (If known at this point in time, please describe as 
specifically as possible the potential sectoral/national benefits arising from 
the project and provide an assessment of their significance) 
Established linkage with Mycobacteriology Group, University of Sydney. 
_ The clone product (DNA construct) obtained from this project has potential 
for further vaccine development as an alternative vaccine for the 
prevention and control of TB. 
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Assessment of project structure 
• Project Team (Please provide an assessment of how the project team perfonned 
and highlight any significant departure from plan in either structure or actual man-
days utilised) 
- Assoc. Prof. Dr. Mustaffa: overall management of the project, supervising 
immunogenicitiy studies (10 man-months) 
Assoc. Prof. Dr. Zainul: organising PCR analyses and DNA cloning (4 man-
months) 
RO (Pn. Salwana Ahmad): performing all laboratory works (36 man-months) 
• Collaborations (Please describe the nature of collaborations with other research 
organisations and/or industry) 
CoJaboration with Mycobacteriology laboratory (Assoc. Prof. W. ·Britton). Centenary 
tnstitute for Cancer Medicine & Cell Biology, University of Sydney with regards to 
the infonnation on the latest technology in DNA vaccine development. 
Assessment of Research Approach (Please highlight the main steps actually performed 
and indicate any major departure from the planned approach or any major difficulty 
encountered) · 
Main steps: 
1. Designing synthetic gene of M. tuberculosis consist of multipe T -cell epitopes of 
M. tuberculosis using a computer programme (Mac DNAsis & Oligo programme) 
and generation of oligonucleotides based of the gene construct (vacll). 
Perfonning Assembly PCR to construct the vacll. 
2. Cloning of the vacll gene into an expression vector (a DNA vaccine vector -
pJW4303) and analyses of the recombinant clones by PCR, restriction digest 
and DNA sequencing. 
3. Vaccination mice with pJWvacll and pJW4303 (control) for immunogenicity 
studies. 
6. Lymphocyte Transformation Test and IFN gamma production assay. 
Assessment of the Project Schedule (Please make any relevant comment regarding the 
actual duration of the project and highlight any significant va_riation from plan) 
The project was running according to project schedule except at the beginning of 
the project due to time consumed for purchasing of reagents and training of the 
research officer. 
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Technology Transtertcommercialisation Approat:h ~lease desaibe the approach planned to 
transfer/commercialise the results of the project} 
• Patent (P!esse state full title or the patent by gvmg the patent number or epp8cati<Jn number) 
Nil 
• Publication pertaining to.the research finding 
. (a) Report/Conference Paper 
1. ·construction of synthetic genes of Mycobacterium tuberculosis using 
assembly PCR technique. 1oth MSMBB Scientific Meeting;14-16th May 2000, 
Hyatt Regency Saujana, Subang. (see Appendix B) 
2. 'Construction of synthetic gene of Mycobacterium tuberculosis: towards the. 
development of DNA vaccine against tuberculosis ... Global alliance for TB 
drug Development Conference on R & D coalition for TB drug development 
in Asia. May 2nd -4th, 2001. Penang Parkroyal Resort Batu Feringghi Beach, 
11100 Batu Feringghi, Penang, Malaysia. 
3.Norazmi Mohd Nor and Mustaffa Musa (2001 ). 'Potential approaches towards 
the development of a vaccine against tuberculosis: Recombinant BCG and DNA 
vaccine'. Monograph. Biotechnology Symphosia I. UMS. 
(b) Journal Publication (Use only the standard accepted abbreviations for journal titles. If there 
are none, give the fuD joumal title) 
In preparation 
(c) Others: 
1. The Sun: 1oth June 1999 ... New vaccine from USM'. 
2. Utusan Malaysia: 9th June 1999. '"USM researchers construct vaccine prevent 
TB' 
3. Segment 'Good Morning Malaysia', TV1 RTM 5/10/99 on 'TB vaccine 
research activities in PPSP'. 
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a Post Graduates (Who graduated or who are stiH participating the project) 
Student Name 
&Year of Thesis Title PhD/ 
Registration/Nation MSc 
a lily 
Nil 
• No. of Research Assistants or Officers funded by the project: 
{a) Research Officers: 1 (b) Research Assistants: 1 
Collaboration (Please describe the nature of collaborations With other research organizations 
and/or Industry) 
Institutions: 
(a) Local Institutions: Hospital Kota Bharu- provide blood 
samples of TB patients . 
Year of 
completion 
(b) International Institutions: Mycobacterial .Research Group, 
Centenary Institute of Cancer Medicine and Cell Biology (Professor 
Warwick Britton & Dr Adrew Bean). Performing protective/challenge 
studies in mice to compare the protective efficacy of the DNA vaccine 
with BCG-immunised mice. Experiments need to be carried out in the · 
P3 level laboratory which involve aerosol tuberculosis. 
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Details of experimental results of the project 
Objectives of the project 
To construct plasmid DNA expressing mutiple T-cell epitopes of Mycobacterium tuberculosis: 
towards the development of potential DNA vaccine candidates against tuberculosis. 
Methodology 
1. Designing of a synthetic gene {vacll) consist of multipleT-cell spitopes of M. tuberculosis 
using MacDNAsis and OLIGO software (Figure A). 
2. Construction of vacll by assembly PCR technique (Rgure B). 
3. Cloning of vacll into plasmid expression vector, pJW4303. 
4. Immunization protocol for DNA vaccine candidate (Figure C). 
5. lmmunogenicity studies: L TT, ELISA lFNy (Figure D) 
Results 
1. Construction of synthetic gene( designated as vacll) consist of multipleT-cell spitopes of M. 
tuberculosis and cloning of vacll into plasmid expression vector, pJW4303. The recombinant 
clone (designated as pJWvacfl) was secreened by double enzyme digestion (Figure E) and 
confinned by DNA sequencing (Figure F). 
2. lmmunogenicity studies: L TT, ELISA IFNy (Table A & B) 
Conclusion 
We have constructed one plasmid DNA expressing multipleT-cell epitopes of Mycobacterium 
tuberculosis (designated as pJWvacll). Preliminary studies on the immunogenicity of this 
plasmid has been done in mice and the results suggested that this plasmid is potentially useful 
as DNA vaccine candidate for tuberculosis. Further studies that to be done to evaluate this 
vaccine candidate indude protection efficacy in animal model. 
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F\gure A ONA and prote\n· sequence of vac \\ (cons\st of 
selected T-een epitopes of ESAT6, mtp40, 38kD and MPT64 
genes of.M. tuberculosis). 
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\mmun\zat\on Protocol Figure C 
Plasmid DNA injected i.m. into C57BL/6J 
[5 mice for pJWvacll 
5 mice for the plasmid vector pJW] 
n 2 weeks . 
2nd injection 
n 2weeks . 
. 3rd injection 
n 2weeks 
Collect spleeri (lymphocyteS) 
• 
.; 
Figure D 
• 
ELISA IFNy (using commercial kit) 
. HI!~Mtm'I!RbtJtmMM-UlfiJ!L'll-
l s 
Culture S/N is added into wells coated with Ab to IFN y 
JJ 
Washing 
JJ 
Enzyme Ab conjugate is the added 
JJ 
washing 
u 
Enzyme substrate is added and colour reactiOn is measured 
by spectrophotometer (the value of IFN y is calculated 
based on the standard ~urve) 
'.. . ·r~-. - j 
··' ·. 
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M 1 
-S.lkb . 
(vector; pJW43.03) 
lOOObp. 
882bp 
(insert; Vac IT) 
500bp 
Figure ' '& Electrophoresis of recombinant clone (pJWVac II) after double 
enzyme digestion with Nhel and Bam HI (Lane M: 1 OObp DNA ladder, lc;tne 1: 
clone pJWVacl l digested with BamHI and Nhel) 
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Confirmation by DNA sequencing 
ESAT mtp40 
MTEQQWNFAGIEAAASAIQGNANPYQGVQQKWDATATELNNALQNANPASMLGT 
MTEQQWNFAGIEAAASAIQGNANPYQGVQQKWDATATELNNALQNANPASMLGT 
38kD 
VTNSPGVPGGAVGGVTWSKKPPFSSNANPMKIRLHTLLAVLTAAPLLLANANPI 
VTNSPGVPGGAVGGVTWSKKPPFSSNANPMKIRLHTLLAVLTAAPLLLANANPI 
AVGGVTWSKKPPFSSNANPMKIRLHTLLAVLTAAPLLLANANPI 
ALAISAQQVNYNLPGVSEHLNANPALGENGNGGMVTGCAETPGCVAYIGISFLD 
ALAISAQQVNYNLPGVSEHLNANPALGENGNGGMVTGCAETPGCVAYIGISFLD 
ALAISAQQVNYNLPGVSEHLNANPALGENGNGGMVTGCAETPGCVAYIGISFLD 
QASQRGLGEAQLGNSNANPINYEYAIVNNRQKDAATAQTLQAFLHWAITDGNAN 
QASQRGLGEAQLGNSNANPINYEYAIVNNRQK 
QASQRGLGEAQLGNSNANPINYEYAIVNNRQKDAATAQTLQAFLHWAITDGNAN 
MPT64 
PPVNYQNFAVTNDGVIFFFNPGELLPEAAGPTQVLVPRSAIDSMLANANPNANP 
PPVNYQNFAVTNDGVIFFFNPGELLPEAAGPTQVLVPRSAIDSMLANANPNANP 
Figure F. 
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LYMPHOCYTE TRANSFORMATION TEST (LTT) 
Table A: Stmulation Index (SI) of lymphocyte cultures from mice 
vaccinated with pJWvacii (U) and control mice (K) vaccinated with 
pJW4303 (blank plasmid ) after stimulation with various vacll peptides 
(Sug/ml). 
1 
Kl K2 K3 
POOLED 0.8 0.21 2.2 
0./ 0.6 1.0 
1.0 1.0 0.7 
1.0 0.3 0.5 
0.7 0.4 1.1 
0.11 0.6 0.9 
. 
0.3 1.0 2.0 
38A lOug 0.04 1.02 3.3 
38BSug 0.1 0.4 1.7 
38B lOug 0.14 1.5 0.9 
64A5ug 0.11 1.1 1.8 
64A 10ug 0.13 0.5 0.9 
nt 2 
K4 KS 
POOLED 1.8 1.1 
2.5 3.1 
ESAT 1.5 0.5 
5. 
ESAT 5.2 1.4 
10. 
38A5ug/ml 0.8 0.5 
12 
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38B5ug 0.7 0.3 
38B lOug 1.4 0.8 
• 
64A5ug 0.4 0.6 
• 
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ELISAIFN 
Table B: Production of IFNy (ug!ml) by lymphocyte cultures from mice 
vaccinated with pJWvacll (U) and control mice (K) vaccinated with 
pJW4303 (blank plasmid) after stimulation with various vacll peptides. 
Experiment 1 
Kl 
Pooled 
peptides 500 
(Sug/ml) 
ESAT6 65 
100 
900 
•• · - \.. ·• a' •• 
K2 
1750 
365 
>1,000 
150 
, ~ . , ~·r .' i-: . • . • . 
K3 
1100 
35 
100 
550 
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Appendix B: Paper presented at1 Oth MSMBB Scientific Meeting; 14-16th May 
2000, Hyatt Regency Saujana, Subang (Poster PS). 
"Construction of synthetic genes of Mycobacterium 
tuberculosis using assembly PCR technique'' 
Mustaffa Musa , Salwana Ahmad & Zainuf F. Zainuddin*Department 
of Immunology, School of Medical Sciences, School of Health 
Sciences*, Universiti Sains Malaysia, 16150 Kubang Kerian, 
Kelantan. 
Abstract 
The development of improved subunit vaccines is considered a high 
priority in the effort to control TB worldwide. Naked DNA or genetic 
vaccination is the current concept in vaccinology with the -use of 
plasmid DNA expressing certain gene. Single or multiple gene~ of an 
organism can be cloned into the expression plasmids. In our ··study, 
assembly PCR technique was used to construct a synthetic genes 
namely, Vac Vac II. (0.82 kb). This synthetic gene were based on 
ESATS, mtp40, mtp64 and 38kD genes of M. tuberculosis. Vac II 
gene consist of selected T -cell epitopes of those four MTB genes. In 
assembly PCR technique, mixture of Vac II derived-oligos was 
amplified for 55 cycles {950C/30sec, 620C/30sec, 720C/30sec). The 
PCR product with the expected DNA band size was reamplified using 
vector cloning primers (Nhe 1 and Bam HI primers). The final PCR 
products of Vac II are ready to be cloned into the expression vector. 
Introduction 
Tuberculosis is a major bacterial disease of humans accounting for 8 
million cases of clinical disease and 3 million deaths annually. The 
development of improved subunit vaccines is considered a high 
priority in the effort to control TB worldwide. DNA vaccines are a 
new and powerful approach to the generation of the needed vaccines 
(1-4). Dubbed as the .. third revolution" in vaccine development, this 
novel method of immunization relies on plasmid expression vectors 
to produce the immunizing protein(s) in the vaccinated host. It 
involves direct Injection of plasmids, loops of DNA that contains 
genes for proteins produced by the organism targeted for immunity. 
Once injected into the host muscle tissue, the DNA is taken up by 
host cells, which then start expressing the foreign protein. The 
protein serves as an antigen that stimulates immune responses. 
Materials and Methods 
Overlapping oligos (19 upper strand + 19 lower strand) based on the 
DNA sequence of the synthetic gene (vac II - see Figure 1) were 
designed using a computer programme (Oligo 5 & McDNAsis). 
Oligos were commercially made by Operon TeChnologies Inc. and 
BioBasic Inc. through Bionsyntech Sdn. Bhd. Assembly PCR was 
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performed with slight modification according to the method described 
by Stemmer eta/. (5). This technique involves 2 steps (Figure 2); 1st 
step: ovalapping oligos were mixed in PCR reaction buffer, amplified 
for 55 cycles (950C/30sec, 620C/30sec, 720C/30sec). 2nd Step: 
PCR product of the first step (with the expected band size) was re-
PCR (950C/30sec, 620CJ30sec, 720C/30sec) using vector cloning 
primers (Nhe11BamH1 primer) for 55 cycles. The PCR products were 
analysed by agarose gel electrophoresis. 
Results and Discussion . 
AssembJy PCR (1st step PCR) using the Vac II oligos showed smear 
band when ~nalysed with agarose gel electrophoresis (Figure 3A). 
From the first step product as a template, we did the 2nd step PCR 
using the cloning primers (Nhe I dan Bam H 1). We managed to get 
the correct size of the product which was 0.82kb (Vac II) (Figure 38). 
The synthetic gene is being cloned into plasmid expression yector 
(pJW4303) for further analysis. Such analysis included DNA 
sequencing to determine the gene sequences and whether the gene 
is in frame or not. The results showed that assembly PCR technique 
employed in this study were able to generate selected genes of M. 
tuberculosis. It shows that assembly PCR technique is a useful toof 
to generate synthetic gene or multiple genes for the development of 
DNA vaccine. 
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